Hysterectomy, with or without oophorectomy, increases the chances of developing cardiovascular disease in women younger than 50 years of age, a study from the Karolinska Institutet, Stockholm, Sweden, indicates.
Hysterectomy, with or without oophorectomy, increases the chances of developing cardiovascular disease in women younger than 50 years of age, a study from the Karolinska Institutet, Stockholm, Sweden, indicates.
Researchers compared 184,441 Swedish women, identified from nationwide health care registers, who had a hysterectomy for benign indications between 1973 and 2003, with controls who didn’t undergo hysterectomy. The primary outcome measure was first hospitalization or death caused by incident cardiovascular disease (ie, coronary heart disease, stroke, or heart failure), as determined by linking individual patients to the Swedish Inpatient Register.
Women younger than 50 years had a significantly higher risk of both coronary heart disease and stroke after hysterectomy than controls. The increase was independent of socioeconomic status. Women older than 50 years showed no significant association between hysterectomy and cardiovascular disease.
The authors conclude that hysterectomy in women 50 years or younger “substantially increases” the risk of cardiovascular disease in later life and that oophorectomy adds to the risk of both coronary heart disease and stroke.
“Before, it was thought that only women undergoing oophorectomy had an increased cardiovascular risk, but our results show that hysterectomy alone is also associated with a raised risk of heart disease,” notes senior author Daniel Altman, MD. Removal of the uterus may affect the blood supply to the ovaries and push women into early menopause, he speculates.
Altman notes that the study results have global or important implications for women’s health in light of the trend toward more hysterectomies at earlier ages to treat a variety of gynecologic conditions. Cardiovascular risk should be considered before recommending hysterectomy, he says.
The study was published online December 24 in the European Heart Journal.
FDA approves updated label for Biktarvy against HIV-1
April 26th 2024Gilead Sciences has announced FDA approval of an updated Biktarvy label, showcasing safety and efficacy data from a phase 1b trial, positioning it as a pivotal treatment option for pregnant individuals with HIV-1 and suppressed viral load.
Read More
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
SART data indicates rise in IVF use in 2022
April 24th 2024Dive into the latest statistics from the Society for Assisted Reproductive Technology, revealing a 6% increase in in vitro fertilization cycles and a surge in egg freezing, amidst a landscape of rising fertility service demand and evolving clinical practices.
Read More